Insys Therapeutics, Inc.
Case Number:
1:19-bk-11292
Court:
Nature of Suit:
Firms
- Hutchison & Steffen
- Rosner Law Group LLC
- Ferry Joseph
- Chamberlain Hrdlicka
- Whiteford Taylor
- Holland & Knight
- Potter Anderson
- Patterson Belknap
- Consovoy McCarthy
- Pachulski Stang
- Stoel Rives
- Chiesa Shahinian
- Wilson Sonsini
- Chipman Brown
- Hughes Hubbard
- Weil Gotshal
- Akin Gump
- Pillsbury Winthrop
- Sills Cummis
- Benesch
- Womble Bond
- Eckert Seamans
- Landis Rath
- Reid Collins
- ASK LLP
- Faegre Drinker
- McCarter & English
- Connolly Gallagher
- May Potenza
- Halperin Battaglia
- Bielli & Klauder
- Richards Layton
- Sullivan Hazeltine
- Cole Schotz
- Blank Rome
- Lowenstein Sandler
- Theodora Oringher
- KP Law Limited
- Morris Nichols
- Montgomery McCracken
- McDermott Will & Emery
- Duane Morris
- Shipman & Goodwin
- Robins Kaplan
- Bonville & Howard
- Skadden Arps
- Stevens & Lee
- Hogan McDaniel
- Brown Rudnick
- Hagens Berman
- Buchanan Ingersoll
- Howard & Howard
- Barrett Law Group
- Gilbert LLP
- Wagstaff & Cartmell
- Keller Postman
- Klehr Harrison
- Seward & Kissel
- Young Conaway
- Cross & Simon
- Orlans PC
- Mayer Brown
Companies
- The Cigna Group
- Iron Mountain Inc.
- Salt River Project
- The Children's Hospital of Philadelphia
- Covance Inc.
- Pioneer Telephone Cooperative Inc.
- H.D. Smith LLC
- Cencora Inc.
- Bessemer Group Inc.
- Ernst & Young LLP
- Ironshore Inc.
- FTI Consulting Inc.
- Receptor Life Sciences
- Lazard Ltd.
- McKesson Corp.
- Johnson & Johnson
- Toyota Motor Corp.
- Cardinal Health Inc.
Government Agencies
- Texas Comptroller of Public Accounts
- Pennsylvania Department of Human Services
- State of Nevada
- Missouri Department of Revenue
- California Department of Health Care Services
- State of Maryland
- State of Michigan
- State of Indiana
- Commonwealth of Kentucky
- New York State Department of Health
Sectors & Industries:
-
August 01, 2024
Insys Trust Sees $6M Clawback For Ex-CEO's Defense Upheld
A Delaware federal judge has ruled a liquidating trust for drugmaker Insys Therapeutics can claw back $6 million paid out for the criminal defense of ex-CEO John Kapoor, affirming a bankruptcy court's ruling last year.
-
January 23, 2024
Ex-CEO's Counterclaims Not Allowed, Insys Trustee Says
The liquidation trustee of Insys Therapeutics on Tuesday asked a Delaware bankruptcy judge for an injunction preventing the pharmaceutical company's former CEO Michael L. Babich from pursuing counterclaims in a clawback suit from the trustee in Delaware's Chancery Court.
-
August 17, 2023
Judge Says Ex-Insys CEO Has To Repay $6M In Defense Fees
A Delaware bankruptcy judge Thursday found the liquidating trustee for drugmaker Insys Therapeutics can claw back $6 million it paid for the criminal defense of ex-CEO John Kapoor, saying Kapoor can't claim his defense was successful after serving prison time for the charges.
-
June 07, 2023
Ex-Insys CEO Says Legal Fee Clawback Unsupported In Ch. 11
The former CEO of drugmaker Insys Therapeutics told a Delaware bankruptcy judge Wednesday that he shouldn't have to return $6 million in legal fees the company advanced to him for criminal defense costs because he was partially successful in his defense, despite a conviction that came with jail time.
-
April 07, 2023
Insys Ch. 11 Trustee Slams Kapoor's Legal Fee Clawback Bid
A bankruptcy trustee for Insys Therapeutics has urged a Delaware judge to order imprisoned former company CEO John Kapoor to return nearly $6 million paid by Insys for his felony racketeering defense, arguing that Kapoor wrongly claimed that some cash went to dropped actions or civil matters.
-
January 16, 2020
Insys Wins OK For Ch. 11 Plan With Opioid Recovery Trust
Bankrupt drugmaker Insys Therapeutics Inc. secured confirmation in Delaware on Thursday for a Chapter 11 liquidation and recovery trust that could initially make $160 million available for victims of an opioid epidemic whose potential claims could climb into the billions.
-
January 09, 2020
Chubb Says Insys Ch. 11 Plan Unclear On Insurance Terms
A number of Chubb Group companies Thursday filed an objection to pain medication maker Insys Therapeutics Inc.'s Chapter 11 plan, saying it would create confusion about how their policy obligations would be treated.
-
January 06, 2020
SEC Says Insys 3rd-Party Releases Should Be Opt-In
The U.S. Securities and Exchange Commission on Monday urged the Delaware bankruptcy court to reject the third-party liability releases in pain medication maker Insys Therapeutics Inc.'s Chapter 11 plan, saying the releases need the OK of shareholders and others.
-
December 02, 2019
Insys Files New Ch. 11 Plan Reflecting Deal With DOJ, States
Bankrupt opioid maker Insys Therapeutics Inc. filed an amended Chapter 11 plan Friday in Delaware that reflects the negotiated agreement reached among the debtor and its creditors, including the U.S. Department of Justice and numerous states, municipalities and Native American tribes.
-
November 21, 2019
Insys Reaches Creditor Deal For Tiered Ch. 11 Recoveries
Bankrupt opioid maker Insys Therapeutics Inc. told a Delaware bankruptcy judge Thursday that negotiations over the past week had resulted in a deal with its creditors on a Chapter 11 plan that will provide tiered recoveries to claimants in different classes.